Immunocore (NASDAQ:IMCR) Sets New 12-Month Low at $25.30

Immunocore Holdings plc (NASDAQ:IMCR)’s share price reached a new 52-week low on Thursday . The stock traded as low as $25.30 and last traded at $25.76, with a volume of 4909 shares changing hands. The stock had previously closed at $27.50.

Several research firms have recently weighed in on IMCR. Zacks Investment Research upgraded shares of Immunocore from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research report on Wednesday. Oppenheimer began coverage on shares of Immunocore in a research report on Tuesday, October 19th. They set an “outperform” rating and a $56.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $50.20.

The business’s 50-day moving average is $33.63 and its 200 day moving average is $34.63. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.24 and a quick ratio of 5.24.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 10th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.15. The business had revenue of $8.17 million during the quarter, compared to analysts’ expectations of $6.92 million. As a group, analysts forecast that Immunocore Holdings plc will post -3.95 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans grew its holdings in Immunocore by 0.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 350,214 shares of the company’s stock worth $12,983,000 after acquiring an additional 1,400 shares during the last quarter. UBS Group AG grew its holdings in Immunocore by 16.5% in the 3rd quarter. UBS Group AG now owns 14,001 shares of the company’s stock worth $519,000 after acquiring an additional 1,987 shares during the last quarter. Wellington Management Group LLP grew its holdings in Immunocore by 260.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,052,075 shares of the company’s stock worth $39,000,000 after acquiring an additional 760,563 shares during the last quarter. Bain Capital Public Equity Management II LLC grew its holdings in Immunocore by 34.5% in the 3rd quarter. Bain Capital Public Equity Management II LLC now owns 638,205 shares of the company’s stock worth $23,658,000 after acquiring an additional 163,651 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Immunocore by 104.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 149,000 shares of the company’s stock worth $5,523,000 after acquiring an additional 76,100 shares during the last quarter. Institutional investors own 44.09% of the company’s stock.

Immunocore Company Profile (NASDAQ:IMCR)

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Read More: Why are gap-down stocks important?

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.